Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study

Imagem de Miniatura
Arquivos
art_CASTALDELLI-MAIA_Smoking_cessation_treatment_outcomes_among_people_with_and_2018.PDF (389.47 KB)
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2018
Editora
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
LORETO, Aline Rodrigues
GUIMARAES-PEREIRA, Bruna Beatriz Sales
CARVALHO, Carlos Felipe Cavalcanti
GIL, Felipe
FRALLONARDO, Fernanda Piotto
ISMAEL, Flavia
VENTRIGLIO, Antonio
RICHTER, Kimber P.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
EUROPEAN PSYCHIATRY, v.52, p.22-28, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: There is a lack of studies evaluating smoking cessation treatment protocols which include people with and without mental and substance use disorders (MSUD), and which allows for individuals with MSUD undergoing their psychiatric treatment. Methods: We compared treatment success between participants with (n = 277) and without (n = 419) MSUD among patients in a 6-week treatment provided by a Brazilian Psychosocial Care Center (CAPS) from 2007 to 2013. Sociodemographic, medical and tobacco use characteristics were assessed at baseline. Tobacco treatment consisted of 1) group cognitive behavior therapy, which included people with and without MSUD in the same groups, and 2) pharmacotherapy, which could include either nicotine patches, nicotine gum, bupropion or nortriptyline. For participants with MSUD, tobacco treatment was integrated into their ongoing mental health treatment. The main outcome was 30-day point prevalence abstinence, measured at last day of treatment. Results: Abstinence rates did not differ significantly between participants with and without MSUD (31.1% and 34.4%, respectively). Variables that were significantly associated with treatment success included years smoking, the Heaviness of Smoking Index, and use of nicotine patch or bupropion. Conclusion: The inclusion of individuals with and without MSUD in the same protocol, allowing for individuals with MSUD undergoing their psychiatric treatment, generates at least comparable success rates between the groups. Predictors of treatment success were similar to those found in the general population. Facilities that treat patients with MSUD should treat tobacco use in order to reduce the disparities in morbidity and mortality experienced by this population.
Palavras-chave
Smoking, Tobacco, Treatment, Mental health, Substance use disorders
URI
https://observatorio.fm.usp.br/handle/OPI/28240
Referências
  1. American Legacy Foundation, 2011, HIDD EP TOB US MENT
  2. Anthenelli RM, 2016, LANCET, V387, P2507, DOI 10.1016/S0140-6736(16)30272-0
  3. Aveyard P, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000027
  4. Batra A, 2009, NERVENARZT, V80, P1022, DOI 10.1007/s00115-009-2744-y
  5. Cahill K., 2013, COCHRANE DB SYST REV, V5, DOI [10.1002/14651858.CD009329.pub2, DOI 10.1002/14651858.CD009329.PUB2]
  6. Capron DW, 2014, ADDICT BEHAV, V39, P782, DOI 10.1016/j.addbeh.2013.12.014
  7. Castaldelli-Maia JM, 2016, INT J SOC PSYCHIATR, V62, P411, DOI 10.1177/0020764016642491
  8. Castaldelli-Maia JM, 2014, INT REV PSYCHIATR, V26, P515, DOI 10.3109/09540261.2014.928272
  9. Castaldelli-Maia JM, 2013, REV BRAS PSIQUIATR, V35, P338, DOI 10.1590/1516-4446-2012-0907
  10. Chengappa KNR, 2014, J CLIN PSYCHIAT, V75, P765, DOI 10.4088/JCP.13m08756
  11. Colton Craig W, 2006, Prev Chronic Dis, V3, pA42
  12. Etter JF, 1999, ADDICTION, V94, P269, DOI 10.1046/j.1360-0443.1999.94226910.x
  13. Evins AE, 2007, J CLIN PSYCHOPHARM, V27, P380, DOI 10.1097/JCP.0b013e3180ca86fa
  14. Evins AE, 2015, HARVARD REV PSYCHIAT, V23, P90, DOI 10.1097/HRP.0000000000000063
  15. Evins AE, 2005, J CLIN PSYCHOPHARM, V25, P218, DOI 10.1097/01.jcp.0000162802.54076.18
  16. Fagerstrom K, 2009, CURR MED RES OPIN, V25, P511, DOI [10.1185/03007990802707568, 10.1185/03007990802707568 ]
  17. Hitsman B, 2009, CAN J PSYCHIAT, V54, P368, DOI 10.1177/070674370905400604
  18. Lasser K, 2000, JAMA-J AM MED ASSOC, V284, P2606, DOI 10.1001/jama.284.20.2606
  19. Loreto AR, 2017, J DUAL DIAGN, V13, P238, DOI 10.1080/15504263.2017.1328149
  20. McFall M, 2010, JAMA-J AM MED ASSOC, V304, P2485, DOI 10.1001/jama.2010.1769
  21. Mielke FB, 2009, CIENC SAUDE COLETIVA, V14, P159, DOI 10.1590/S1413-81232009000100021
  22. Miranda Lilian, 2008, Rev. Saúde Pública, V42, P907, DOI [10.1590/S0034-89102008005000051, 10.1590/s0034-89102008000500017]
  23. Morisano D, 2009, CAN J PSYCHIAT, V54, P356, DOI 10.1177/070674370905400603
  24. Pachas GN, 2012, J DUAL DIAGN, V8, P117, DOI 10.1080/15504263.2012.663675
  25. Prochaska JJ, 2008, AM J PUBLIC HEALTH, V98, P446, DOI 10.2105/AJPH.2006.101147
  26. Prochaska JJ, 2010, JAMA-J AM MED ASSOC, V304, P2534, DOI 10.1001/jama.2010.1759
  27. Raw M, 2009, ADDICTION, V104, P1243, DOI 10.1111/j.1360-0443.2009.02584.x
  28. Roberts E, 2016, ADDICTION, V111, P599, DOI 10.1111/add.13236
  29. Schroeder SA, 2010, ANNU REV PUBL HEALTH, V31, P297, DOI 10.1146/annurev.publhealth.012809.103701
  30. Shiffman S, 2000, PSYCHOPHARMACOLOGY, V148, P33, DOI 10.1007/s002130050022
  31. Stead LF, 2012, COCHRANE DB SYST REV, V11, DOI 10.1002/14651858.CD000146.PUB4
  32. Stead LF, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008286.pub3
  33. Strong DR, 2009, NICOTINE TOB RES, V11, P1142, DOI 10.1093/ntr/ntp111
  34. Taylor M, 2011, ADDICTION, V106, P1819, DOI 10.1111/j.1360-0443.2011.03493.x
  35. Walker N, 2014, NEW ENGL J MED, V371, P2353, DOI 10.1056/NEJMoa1407764
  36. Willenbring ML, 2004, J SUBST ABUSE TREAT, V26, P79, DOI 10.1016/S0740-5472(03)00161-2
  37. World Health Organization, 2011, WHO REP GLOB TOB EP
  38. Ziedonis D, 2008, NICOTINE TOB RES, V10, P1691, DOI 10.1080/14622200802443569

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Carregar mais